AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) announced that CEO Thomas K. Equels will participate in the Virtual Investor Lunch Break Series on June 5, 2024, at 12:00 PM ET. During the event, Mr. Equels will give a corporate overview and discuss the company's business outlook. Attendees can submit questions live, which Mr. Equels will address. The live webcast will be available on the company’s website, and a replay will be accessible for 90 days two hours after the presentation.

Positive

• CEO Thomas K. Equels will provide a corporate overview, offering transparency to investors.
• Opportunity for investors to submit live questions and receive direct answers from the CEO.
• Webcast accessibility on the company's website, with replay available for 90 days.

Negative

• The press release lacks specific financial or clinical data updates.
• No mention of recent achievements or future plans that could positively impact stock performance.
• Absence of detailed information on business developments or strategic initiatives.

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET

OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series on Wednesday, June 5, 2024 at 12:00 PM ET.

As part of the event, Mr. Equels will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Equels will answer as many questions as possible in the time allowed.

A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

FAQ

When will AIM ImmunoTech's CEO participate in the Virtual Investor Lunch Break Series?

June 5, 2024, at 12:00 PM ET.

How can I watch the live webcast of AIM ImmunoTech's CEO presentation?

The live webcast will be available on the Events page of the company's website.

Will there be a recording available for AIM ImmunoTech's Virtual Investor Lunch Break Series presentation?

Yes, a webcast replay will be available two hours after the live presentation and will be accessible for 90 days.

What will AIM ImmunoTech's CEO discuss during the Virtual Investor Lunch Break Series?

CEO Thomas K. Equels will provide a corporate overview and business outlook.

Can attendees ask questions during AIM ImmunoTech's Virtual Investor Lunch Break Series?

Yes, attendees can submit questions live during the event, and Mr. Equels will answer as many as possible within the time allowed.